New Perspectives in HCV Therapy: Entry Inhibitors

Author(s): Marco Donia, Bruno Cacopardo, Massimo Libra, Guido Scalia, James A. McCubrey, Ferdinando Nicoletti

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 5 , Issue 3 , 2010

Become EABM
Become Reviewer

Abstract:

Despite the improvements in HCV-therapy achieved in the last 20 years, the occurrence of high frequency of non-responders and of therapy-related side effects has lead to an ongoing interest in optimizing duration and dosage of current antiviral regimens as well as to the research and development of new antiviral treatment. Recently, the discovery of a system for in vitro HCV replication provided a useful tool for a better understanding of the viral life cycle followed by the discovery of new compounds that unlike classical drugs specifically target fundamental steps of this process. The aim of this review is to provide an update on the preclinical and clinical development of novel anti-HCV treatments targeting the first steps of the viral life cycle. The recent patents in this review article discuss the new perspectives in HCV therapy.

Keywords: HCV, entry inhibitors, preclinical development, clinical development, HCV-therapy, antiviral treatment, replication, anti-HCV treatments, flavivirus, Chronic, acute, cirrhosis, hepatocellular, glomerulonephritis, cryoglobulinemia, porphyria cutanea tarda, lymphoproliferative, liver transplantation, HCC, prognosis, fibrosis, IFN-alpha, ribavirin, peginterferon, PEG-IFN, viral RNA, anaemia, thrombocytopenia, Hepacivirus, Flaviviridae, heterodimer, glycosaminoglycans, glycoprotein, drug design, albumin, Boceprevir, Telaprevir, Albinterferon alpha-2b, luciferase assay, liver-uPA-SCID, Viral Envelope, epitopes, monoclonal antibodies, plasma donor antibodies, polyclonal antibodies, HCV-genotypes, Glycosylation, glycans, cyanovirin-N, high-mannose oligosaccharides, iminosugars, BVDV, adenovirus, vaccinia virus, canary pox virus, alphavirus, CD81, tetraspanin, endocytosis, Claudin-1, Occludin, CLDN1, chlorpromazine, chloroquine, concanamycin A, bafilomycin, Heparin, Heparinase, Lamiridosins, Phosphorothioate, Oligonucleotides (PS-ONs), Arbidol, C5A, amphipathic-helical peptide, paramyxoviruses, SP-30, PRO 206, Civacir, ITX5061, REP 9AC, JTK-652, immune serum globulin, placebo, monotherapy, clinical trials, Lamiaceae

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 5
ISSUE: 3
Year: 2010
Page: [181 - 194]
Pages: 14
DOI: 10.2174/157489110793348802
Price: $58

Article Metrics

PDF: 5